Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water ...

Idexx Laboratories (IDXX) reported $1.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.6%. EPS of $3.63 for the same period compares to $2.44 a year ...

Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a narrow moat. It is well-positioned to benefit from two key trends. First, pet ownership ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Idexx Laboratories (IDXX) reports results for the quarter ended September 2025. While this widely-known consensus ...

Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay ...

Idexx posted second-quarter results that were more muted than usual; we’re leaving our fair value estimate unchanged as our slight adjustments to full-year projections weren’t enough to move the ...

If you are wondering whether IDEXX Laboratories is still fairly priced after a strong run, this article walks through what the current share price could mean for long term investors. The stock last ...

Upgraded IDEXX to 'Buy' with a $450 price target due to oncology business expansion and share repurchase program. IDEXX's oncology market entry with Cancer Dx panel in March 2025 could drive ...

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...